- Home
- Publications
- Publication Search
- Publication Details
Title
New approaches to symptomatic treatments for Alzheimer’s disease
Authors
Keywords
-
Journal
Molecular Neurodegeneration
Volume 16, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-13
DOI
10.1186/s13024-021-00424-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial
- (2020) W. Joseph Herring et al. Alzheimers & Dementia
- Lemborexant: First Approval
- (2020) Lesley J. Scott DRUGS
- The Neuropsychiatric Inventory: Development and Applications
- (2020) Jeffrey Cummings JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY
- Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
- (2020) Shorena Janelidze et al. NATURE MEDICINE
- Distinct Symptom-Specific Treatment Targets for Circuit-Based Neuromodulation
- (2020) Shan H. Siddiqi et al. AMERICAN JOURNAL OF PSYCHIATRY
- A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
- (2020) Kenneth S. Koblan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of Run-in Periods in Randomized Trials
- (2020) Xiqian Huo et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease
- (2020) Giacomo Koch et al. JAMA Network Open
- Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer’s Disease
- (2020) Jeffrey Cummings JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
- The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans
- (2019) Jerrah K. Holth et al. SCIENCE
- The Alzheimer’s Disease Clinical Spectrum
- (2019) Alireza Atri MEDICAL CLINICS OF NORTH AMERICA
- Novel pathways in the treatment of Major Depression: focus on the glutamatergic system
- (2019) Carmine Tomasetti et al. CURRENT PHARMACEUTICAL DESIGN
- Randomized placebo controlled trial of nabilone for agitation in Alzheimer's disease
- (2019) Nathan Herrmann et al. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
- Effect of phosphodiesterase (1B, 2A, 9A and 10A) inhibitors on central nervous system cyclic nucleotide levels of rats and mice
- (2019) Jie Chen et al. NEUROCHEMISTRY INTERNATIONAL
- Targeting opioid dysregulation in depression for the development of novel therapeutics
- (2019) Caroline A. Browne et al. PHARMACOLOGY & THERAPEUTICS
- Randomized clinical trials with run-in periods: frequency, characteristics and reporting
- (2019) David Ruben Teindl Laursen et al. Clinical Epidemiology
- Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression
- (2019) Xinyi Wang et al. CELL RESEARCH
- Bidirectional relationship between sleep and Alzheimer’s disease: role of amyloid, tau, and other factors
- (2019) Chanung Wang et al. NEUROPSYCHOPHARMACOLOGY
- The “rights” of precision drug development for Alzheimer’s disease
- (2019) Jeffrey Cummings et al. Alzheimers Research & Therapy
- Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials
- (2019) George T. Grossberg et al. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
- Alzheimer's disease and sleep disturbances: a review
- (2019) Conrado Regis Borges et al. ARQUIVOS DE NEURO-PSIQUIATRIA
- Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents
- (2019) Misae Takakuwa et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Revisiting Criteria for Psychosis in Alzheimer’s Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research
- (2019) Corinne E. Fischer et al. JOURNAL OF ALZHEIMERS DISEASE
- The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
- (2018) Harald Hampel et al. BRAIN
- Cognitive correlates of α4β2 nicotinic acetylcholine receptors in mild Alzheimer’s dementia
- (2018) Osama Sabri et al. BRAIN
- The role of 5 HT6-receptor antagonists in Alzheimer’s disease: an update
- (2018) Rita Khoury et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease
- (2018) Tian Li et al. HIPPOCAMPUS
- Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease
- (2018) Alireza Atri et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy
- (2018) Stuti Verma et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study
- (2018) Clive Ballard et al. LANCET NEUROLOGY
- The Gut Microbiome Alterations and Inflammation-Driven Pathogenesis of Alzheimer’s Disease—a Critical Review
- (2018) Marta Sochocka et al. MOLECULAR NEUROBIOLOGY
- High performance plasma amyloid-β biomarkers for Alzheimer’s disease
- (2018) Akinori Nakamura et al. NATURE
- The Disease-modifying Drug Candidate, SAK3 Improves Cognitive Impairment and Inhibits Amyloid beta Deposition in App Knock-in Mice
- (2018) Hisanao Izumi et al. NEUROSCIENCE
- Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression
- (2018) J. Blair Price et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- The role of dopaminergic midbrain in Alzheimer’s disease: Translating basic science into clinical practice
- (2018) Marcello D’Amelio et al. PHARMACOLOGICAL RESEARCH
- The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial
- (2018) Roberta W. Scherer et al. Trials
- Exploring Data Quality Management within Clinical Trials
- (2018) Yasmine Probst et al. Applied Clinical Informatics
- Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group
- (2018) P. Robert et al. EUROPEAN PSYCHIATRY
- Neurobiological Correlates of Apathy in Alzheimer's Disease and Mild Cognitive Impairment: A Critical Review
- (2018) Florindo Stella et al. JOURNAL OF ALZHEIMERS DISEASE
- Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis
- (2018) Chen-Chen Tan et al. JOURNAL OF ALZHEIMERS DISEASE
- Why Do They Just Sit? Apathy as a Core Symptom of Alzheimer Disease
- (2018) Carolyn W. Zhu et al. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
- Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials
- (2018) Kai-Xin Dou et al. Alzheimers Research & Therapy
- A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers
- (2017) Katja Boland et al. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
- New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
- (2017) Albert Yang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)
- (2017) Stephane Nave et al. JOURNAL OF ALZHEIMERS DISEASE
- Efficacy of Antidepressants for Depression in Alzheimer’s Disease: Systematic Review and Meta-Analysis
- (2017) Vasiliki Orgeta et al. JOURNAL OF ALZHEIMERS DISEASE
- Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer’s Disease
- (2017) Thomas N. Chase et al. Neurotherapeutics
- Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials
- (2016) Jeff Sevigny et al. ALZHEIMER DISEASE & ASSOCIATED DISORDERS
- The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer’s disease
- (2016) Xun-Hu Gu et al. BEHAVIOURAL BRAIN RESEARCH
- Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?
- (2016) Debby Van Dam et al. Current Alzheimer Research
- The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysis
- (2016) Qing-Fei Zhao et al. JOURNAL OF AFFECTIVE DISORDERS
- Cognitive-Enhancing Effects of a Polyphenols-Rich Extract from Fruits without Changes in Neuropathology in an Animal Model of Alzheimer’s Disease
- (2016) Alexandre Dal-Pan et al. JOURNAL OF ALZHEIMERS DISEASE
- ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
- (2016) Jinping Wang et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Alzheimer's disease
- (2016) Philip Scheltens et al. LANCET
- Noradrenergic System in Down Syndrome and Alzheimer's Disease A Target for Therapy
- (2015) Cristy Phillips et al. Current Alzheimer Research
- Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
- (2015) Joshua D. Rosenblat et al. Current Neuropharmacology
- Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial
- (2015) Paul B. Rosenberg et al. INTERNATIONAL PSYCHOGERIATRICS
- Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia
- (2015) Jeffrey L. Cummings et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Neuroinflammation in Alzheimer's disease
- (2015) Michael T Heneka et al. LANCET NEUROLOGY
- Sleep and Alzheimer's disease
- (2015) Laure Peter-Derex et al. SLEEP MEDICINE REVIEWS
- Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis
- (2015) Alireza Atri et al. Alzheimers Research & Therapy
- Alzheimer's disease
- (2015) Colin L. Masters et al. Nature Reviews Disease Primers
- Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease
- (2014) Gerard J. Marek et al. Alzheimers & Dementia
- Computerized Cognitive Testing for Older Adults
- (2014) Stelios Zygouris et al. American Journal of Alzheimers Disease and Other Dementias
- Phosphodiesterase Inhibitors as a Target for Cognition Enhancement in Aging and Alzheimer’s Disease: A Translational Overview
- (2014) P.R.A. Heckman et al. CURRENT PHARMACEUTICAL DESIGN
- Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition
- (2014) Jeffrey Cummings et al. INTERNATIONAL PSYCHOGERIATRICS
- Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
- (2014) Jeffrey L Cummings et al. Alzheimers Research & Therapy
- Psychosis in Alzheimer’s Disease is Associated with Frontal Metabolic Impairment and Accelerated Decline in Working Memory: Findings from the Alzheimer's Disease Neuroimaging Initiative
- (2013) Jeremy Koppel et al. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
- Safety and Efficacy of Methylphenidate for Apathy in Alzheimer’s Disease
- (2013) Paul B. Rosenberg et al. JOURNAL OF CLINICAL PSYCHIATRY
- Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease
- (2013) M.-Marsel Mesulam JOURNAL OF COMPARATIVE NEUROLOGY
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
- (2013) Jeffrey Cummings et al. LANCET
- Sleep and Alzheimer disease pathology—a bidirectional relationship
- (2013) Yo-El S. Ju et al. Nature Reviews Neurology
- Progress in novel cognitive enhancers for cognitive aging and Alzheimer’s disease
- (2013) Diana W Shineman et al. Alzheimers Research & Therapy
- Neurotoxicity of Amyloid -Protein: Synaptic and Network Dysfunction
- (2013) L. Mucke et al. Cold Spring Harbor Perspectives in Medicine
- Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: Application to antidepressant trials
- (2012) Ruud Boessen et al. Clinical Trials
- Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease
- (2012) D.P. Devanand et al. NEW ENGLAND JOURNAL OF MEDICINE
- The placebo response in clinical trials: more questions than answers
- (2011) P. Enck et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease
- (2010) D.P. Devanand et al. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
- Neurochemical basis for symptomatic treatment of Alzheimer's disease
- (2010) Paul T. Francis et al. NEUROPHARMACOLOGY
- Prazosin for the Treatment of Behavioral Symptoms in Patients With Alzheimer Disease With Agitation and Aggression
- (2009) Lucy Y. Wang et al. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
- Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine
- (2009) Joanne Rodda et al. INTERNATIONAL PSYCHOGERIATRICS
- M1 Muscarinic Agonists Target Major Hallmarks of Alzheimer’s Disease – The Pivotal Role of Brain M1 Receptors
- (2008) Abraham Fisher Neurodegenerative Diseases
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now